-
1
-
-
80051700067
-
Pancreatic cancer
-
Vincent A, Herman J, Schulick R, Hruban RH, Goggins M. Pancreatic cancer. Lancet 2011;378:607-20.
-
(2011)
Lancet
, vol.378
, pp. 607-620
-
-
Vincent, A.1
Herman, J.2
Schulick, R.3
Hruban, R.H.4
Goggins, M.5
-
2
-
-
77955635233
-
Cancer statistics, 2010
-
Jemal A, Siegel R, Xu J, Ward E. Cancer statistics, 2010. CA Cancer J Clin 2010;60:277-300.
-
(2010)
CA Cancer J Clin
, vol.60
, pp. 277-300
-
-
Jemal, A.1
Siegel, R.2
Xu, J.3
Ward, E.4
-
3
-
-
77951755278
-
Pancreatic cancer
-
Hidalgo M. Pancreatic cancer. New Engl J Med 2010;362:1605-17.
-
(2010)
New Engl J Med
, vol.362
, pp. 1605-1617
-
-
Hidalgo, M.1
-
4
-
-
8244254377
-
Improvements in survival and clinical benefi twith gemcitabine as first-line therapy for patients with advanced pancreas cancer: A randomized trial
-
Burris HA III, Moore MJ, Andersen J, Green MR, Rothenberg ML, Modiano MR, et al. Improvements in survival and clinical benefi twith gemcitabine as first-line therapy for patients with advanced pancreas cancer: a randomized trial. J Clin Oncol 1997;15:2403-13.
-
(1997)
J Clin Oncol
, vol.15
, pp. 2403-2413
-
-
Burris, H.A.1
Moore, M.J.2
Andersen, J.3
Green, M.R.4
Rothenberg, M.L.5
Modiano, M.R.6
-
5
-
-
33846405332
-
Adjuvant chemotherapy with gemcitabine vs observation in patients undergoing curative-intent resection of pancreatic cancer: A randomized controlled trial
-
Oettle H, Post S, Neuhaus P, Gellert K, Langrehr J, Ridwelski K, et al. Adjuvant chemotherapy with gemcitabine vs observation in patients undergoing curative-intent resection of pancreatic cancer: a randomized controlled trial. JAMA 2007;297:267-77.
-
(2007)
JAMA
, vol.297
, pp. 267-277
-
-
Oettle, H.1
Post, S.2
Neuhaus, P.3
Gellert, K.4
Langrehr, J.5
Ridwelski, K.6
-
6
-
-
27544500200
-
A prospective randomized trial comparing standard pancreatoduodenectomy with pancreatoduodenectomy with extended lymphadenectomy in resectable pancreatic head adenocarcinoma
-
Farnell MB, Pearson RK, Sarr MG, DiMagno EP, Burgart LJ, Dahl TR, et al. A prospective randomized trial comparing standard pancreatoduodenectomy with pancreatoduodenectomy with extended lymphadenectomy in resectable pancreatic head adenocarcinoma. Surgery 2005;138:618-28.
-
(2005)
Surgery
, vol.138
, pp. 618-628
-
-
Farnell, M.B.1
Pearson, R.K.2
Sarr, M.G.3
DiMagno, E.P.4
Burgart, L.J.5
Dahl, T.R.6
-
7
-
-
0031918491
-
DNA content and other factors associated with ten-year survival after resection of pancreatic carcinoma
-
Allison DC, Piantadosi S, Hruban RH, Dooley WC, Fishman EK, Yeo CJ, et al. DNA content and other factors associated with ten-year survival after resection of pancreatic carcinoma. J Surg Oncol 1998;67:151-9.
-
(1998)
J Surg Oncol
, vol.67
, pp. 151-159
-
-
Allison, D.C.1
Piantadosi, S.2
Hruban, R.H.3
Dooley, W.C.4
Fishman, E.K.5
Yeo, C.J.6
-
8
-
-
52149123619
-
Core signaling pathways in human pancreatic cancers revealed by global genomic analyses
-
Jones S, Zhang X, Parsons DW, Lin JC, Leary RJ, Angenendt P, et al. Core signaling pathways in human pancreatic cancers revealed by global genomic analyses. Science 2008;321:1801-6.
-
(2008)
Science
, vol.321
, pp. 1801-1806
-
-
Jones, S.1
Zhang, X.2
Parsons, D.W.3
Lin, J.C.4
Leary, R.J.5
Angenendt, P.6
-
9
-
-
38849141696
-
Cancer-associated stromal fibroblasts promote pancreatic tumor progression
-
Hwang RF, Moore T, Arumugam T, Ramachandran V, Amos KD, Rivera A, et al. Cancer-associated stromal fibroblasts promote pancreatic tumor progression. Cancer Res 2008;68:918-26.
-
(2008)
Cancer Res
, vol.68
, pp. 918-926
-
-
Hwang, R.F.1
Moore, T.2
Arumugam, T.3
Ramachandran, V.4
Amos, K.D.5
Rivera, A.6
-
10
-
-
34248141223
-
Tumor-stroma interactions in pancreatic ductal adenocarcinoma
-
Mahadevan D, Von Hoff DD. Tumor-stroma interactions in pancreatic ductal adenocarcinoma. Mol Cancer Ther 2007;6:1186-97.
-
(2007)
Mol Cancer Ther
, vol.6
, pp. 1186-1197
-
-
Mahadevan, D.1
Von Hoff, D.D.2
-
11
-
-
0026462778
-
Overexpression of the epidermal growth factor receptor in human pancreatic cancer is associated with concomitant increases in the levels of epidermal growth factor and transforming growth factor alpha
-
Korc M, Chandrasekar B, Yamanaka Y, Friess H, Buchier M, Beger HG. Overexpression of the epidermal growth factor receptor in human pancreatic cancer is associated with concomitant increases in the levels of epidermal growth factor and transforming growth factor alpha. J Clin Invest 1992;90:1352-60.
-
(1992)
J Clin Invest
, vol.90
, pp. 1352-1360
-
-
Korc, M.1
Chandrasekar, B.2
Yamanaka, Y.3
Friess, H.4
Buchier, M.5
Beger, H.G.6
-
12
-
-
35248866321
-
EGFR genomic gain and aberrant pathway signaling in pancreatic cancer patients
-
Tzeng CW, Frolov A, Frolova N, Jhala NC, Howard JH, Vickers SM, et al. EGFR genomic gain and aberrant pathway signaling in pancreatic cancer patients. J Surg Res 2007;143:20-6.
-
(2007)
J Surg Res
, vol.143
, pp. 20-26
-
-
Tzeng, C.W.1
Frolov, A.2
Frolova, N.3
Jhala, N.C.4
Howard, J.H.5
Vickers, S.M.6
-
13
-
-
84866007085
-
EGF receptor is required for KRAS-induced pancreatic tumorigenesis
-
Ardito CM, Gruner BM, Takeuchi KK, Lubeseder-Martellato C, Teichmann N, Mazur PK, et al. EGF receptor is required for KRAS-induced pancreatic tumorigenesis. Cancer Cell 2012;22:304-17.
-
(2012)
Cancer Cell
, vol.22
, pp. 304-317
-
-
Ardito, C.M.1
Gruner, B.M.2
Takeuchi, K.K.3
Lubeseder-Martellato, C.4
Teichmann, N.5
Mazur, P.K.6
-
14
-
-
84866035571
-
EGF receptor signaling is essential for k-ras oncogene-driven pancreatic ductal adenocarcinoma
-
Navas C, Hernandez-Porras I, Schuhmacher AJ, Sibilia M, Guerra C, Barbacid M. EGF receptor signaling is essential for k-ras oncogene-driven pancreatic ductal adenocarcinoma. Cancer Cell 2012;22:318-30.
-
(2012)
Cancer Cell
, vol.22
, pp. 318-330
-
-
Navas, C.1
Hernandez-Porras, I.2
Schuhmacher, A.J.3
Sibilia, M.4
Guerra, C.5
Barbacid, M.6
-
15
-
-
6044241807
-
The correlation between cytoplasmic overexpression of epidermal growth factor receptor and tumor aggressiveness: Poor prognosis in patients with pancreatic ductal adenocarcinoma
-
Ueda S, Ogata S, Tsuda H, Kawarabayashi N, Kimura M, Sugiura Y, et al. The correlation between cytoplasmic overexpression of epidermal growth factor receptor and tumor aggressiveness: poor prognosis in patients with pancreatic ductal adenocarcinoma. Pancreas 2004;29:e1-8.
-
(2004)
Pancreas
, vol.29
, pp. e1-e8
-
-
Ueda, S.1
Ogata, S.2
Tsuda, H.3
Kawarabayashi, N.4
Kimura, M.5
Sugiura, Y.6
-
16
-
-
0032423809
-
Epidermal growth factor and its receptor as prognostic indicators in Chinese patients with pancreatic cancer
-
Dong M, Nio Y, Guo KJ, Tamura K, Tian YL, Dong YT. Epidermal growth factor and its receptor as prognostic indicators in Chinese patients with pancreatic cancer. Anticancer Res 1998;18:4613-9.
-
(1998)
Anticancer Res
, vol.18
, pp. 4613-4619
-
-
Dong, M.1
Nio, Y.2
Guo, K.J.3
Tamura, K.4
Tian, Y.L.5
Dong, Y.T.6
-
17
-
-
0033805783
-
Molecular prognostic markers in pancreatic cancer
-
Coppola D. Molecular prognostic markers in pancreatic cancer. Cancer Control 2000;7:421-7.
-
(2000)
Cancer Control
, vol.7
, pp. 421-427
-
-
Coppola, D.1
-
18
-
-
33644647192
-
Inhibition of SRC expression and activity inhibits tumor progression and metastasis of human pancreatic adenocarcinoma cells in an orthotopic nude mouse model
-
Trevino JG, Summy JM, Lesslie DP, Parikh NU, Hong DS, Lee FY, et al. Inhibition of SRC expression and activity inhibits tumor progression and metastasis of human pancreatic adenocarcinoma cells in an orthotopic nude mouse model. Am J Pathol 2006;168:962-72.
-
(2006)
Am J Pathol
, vol.168
, pp. 962-972
-
-
Trevino, J.G.1
Summy, J.M.2
Lesslie, D.P.3
Parikh, N.U.4
Hong, D.S.5
Lee, F.Y.6
-
19
-
-
0345195986
-
Overexpression and activation of the tyrosine kinase Src in human pancreatic carcinoma
-
Lutz MP, Esser IB, Flossmann-Kast BB, Vogelmann R, Luhrs H, Friess H, et al. Overexpression and activation of the tyrosine kinase Src in human pancreatic carcinoma. Biochem Biophys Res Commun 1998;243:503-8.
-
(1998)
Biochem Biophys Res Commun
, vol.243
, pp. 503-508
-
-
Lutz, M.P.1
Esser, I.B.2
Flossmann-Kast, B.B.3
Vogelmann, R.4
Luhrs, H.5
Friess, H.6
-
20
-
-
1642551021
-
Inhibition of SRC tyrosine kinase impairs inherent and acquired gemcitabine resistance in human pancreatic adenocarcinoma cells
-
Duxbury MS, Ito H, Zinner MJ, Ashley SW, Whang EE. Inhibition of SRC tyrosine kinase impairs inherent and acquired gemcitabine resistance in human pancreatic adenocarcinoma cells. Clin Cancer Res 2004;10:2307-18.
-
(2004)
Clin Cancer Res
, vol.10
, pp. 2307-2318
-
-
Duxbury, M.S.1
Ito, H.2
Zinner, M.J.3
Ashley, S.W.4
Whang, E.E.5
-
21
-
-
2942607458
-
siRNA directed against c-Src enhances pancreatic adenocarcinoma cell gemcitabine chemosensitivity
-
Duxbury MS, Ito H, Zinner MJ, Ashley SW, Whang EE. siRNA directed against c-Src enhances pancreatic adenocarcinoma cell gemcitabine chemosensitivity. J Am Coll Surg 2004;198:953-9.
-
(2004)
J Am Coll Surg
, vol.198
, pp. 953-959
-
-
Duxbury, M.S.1
Ito, H.2
Zinner, M.J.3
Ashley, S.W.4
Whang, E.E.5
-
22
-
-
9744242077
-
Inhibition of SRC tyrosine kinase as treatment for human pancreatic cancer growing orthotopically in nude mice
-
Yezhelyev MV, Koehl G, Guba M, Brabletz T, Jauch KW, Ryan A, et al. Inhibition of SRC tyrosine kinase as treatment for human pancreatic cancer growing orthotopically in nude mice. Clin Cancer Res 2004;10:8028-36.
-
(2004)
Clin Cancer Res
, vol.10
, pp. 8028-8036
-
-
Yezhelyev, M.V.1
Koehl, G.2
Guba, M.3
Brabletz, T.4
Jauch, K.W.5
Ryan, A.6
-
23
-
-
77953898050
-
Dasatinib inhibits the development of metastases in a mouse model of pancreatic ductal adenocarcinoma
-
Morton JP, Karim SA, Graham K, Timpson P, Jamieson N, Athineos D, et al. Dasatinib inhibits the development of metastases in a mouse model of pancreatic ductal adenocarcinoma. Gastroenterology 2010;139:292-303.
-
(2010)
Gastroenterology
, vol.139
, pp. 292-303
-
-
Morton, J.P.1
Karim, S.A.2
Graham, K.3
Timpson, P.4
Jamieson, N.5
Athineos, D.6
-
24
-
-
0034614637
-
The hallmarks of cancer
-
Hanahan D, Weinberg RA. The hallmarks of cancer. Cell 2000;100:57-70.
-
(2000)
Cell
, vol.100
, pp. 57-70
-
-
Hanahan, D.1
Weinberg, R.A.2
-
25
-
-
79952284127
-
Hallmarks of cancer: The next generation
-
Hanahan D, Weinberg RA. Hallmarks of cancer: the next generation. Cell 2011;144:646-74.
-
(2011)
Cell
, vol.144
, pp. 646-674
-
-
Hanahan, D.1
Weinberg, R.A.2
-
26
-
-
0028929803
-
Angiogenesis in cancer, vascular, rheumatoid and other disease
-
Folkman J. Angiogenesis in cancer, vascular, rheumatoid and other disease. Nat Med 1995;1:27-31.
-
(1995)
Nat Med
, vol.1
, pp. 27-31
-
-
Folkman, J.1
-
27
-
-
50249087586
-
A phase II study evaluating bevacizumab in combination with fixed-dose rate gemcitabine and low-dose cisplatin formetastatic pancreatic cancer: Is an anti-VEGF strategy still applicable?
-
Ko AH, Dito E, Schillinger B, Venook AP, Xu Z, Bergsland EK, et al. A phase II study evaluating bevacizumab in combination with fixed-dose rate gemcitabine and low-dose cisplatin formetastatic pancreatic cancer: is an anti-VEGF strategy still applicable? Invest New Drugs 2008;26:463-71.
-
(2008)
Invest New Drugs
, vol.26
, pp. 463-471
-
-
Ko, A.H.1
Dito, E.2
Schillinger, B.3
Venook, A.P.4
Xu, Z.5
Bergsland, E.K.6
-
28
-
-
79958119999
-
Anti-angiogenic agents in pancreatic cancer: A review
-
Assifi MM, Hines OJ. Anti-angiogenic agents in pancreatic cancer: a review. Anticancer Agents Med Chem 2011;11:464-9.
-
(2011)
Anticancer Agents Med Chem
, vol.11
, pp. 464-469
-
-
Assifi, M.M.1
Hines, O.J.2
-
29
-
-
84870998201
-
Structural optimization and structure-activity relationships of N2- (4-(4-Methylpiperazin-1-yl) phenyl)- N8- phenyl-9H-purine-2, 8-diamine derivatives, a new class of reversible kinase inhibitors targeting both EGFR-activating and resistance mutations
-
Yang J, Wang LJ, Liu JJ, Zhong L, Zheng RL, Xu Y, et al. Structural optimization and structure-activity relationships of N2- (4-(4-Methylpiperazin-1-yl) phenyl)- N8- phenyl-9H-purine-2, 8-diamine derivatives, a new class of reversible kinase inhibitors targeting both EGFR-activating and resistance mutations. J Med Chem 2012;55:10685-99.
-
(2012)
J Med Chem
, vol.55
, pp. 10685-10699
-
-
Yang, J.1
Wang, L.J.2
Liu, J.J.3
Zhong, L.4
Zheng, R.L.5
Xu, Y.6
-
30
-
-
66149163097
-
Combined vascular endothelial growth factor receptor and epidermal growth factor receptor (EGFR) blockade inhibits tumor growth in xenograft models of EGFR inhibitor resistance
-
Naumov GN, Nilsson MB, Cascone T, Briggs A, Straume O, Akslen LA, et al. Combined vascular endothelial growth factor receptor and epidermal growth factor receptor (EGFR) blockade inhibits tumor growth in xenograft models of EGFR inhibitor resistance. Clin Cancer Res 2009;15:3484-94.
-
(2009)
Clin Cancer Res
, vol.15
, pp. 3484-3494
-
-
Naumov, G.N.1
Nilsson, M.B.2
Cascone, T.3
Briggs, A.4
Straume, O.5
Akslen, L.A.6
-
31
-
-
79960957703
-
Combining betulinic acid and mithramycin a effectively suppresses pancreatic cancer by inhibiting proliferation, invasion, and angiogenesis
-
Gao Y, Jia Z, Kong X, Li Q, Chang DZ, Wei D, et al. Combining betulinic acid and mithramycin a effectively suppresses pancreatic cancer by inhibiting proliferation, invasion, and angiogenesis. Cancer Res 2011;71:5182-93.
-
(2011)
Cancer Res
, vol.71
, pp. 5182-5193
-
-
Gao, Y.1
Jia, Z.2
Kong, X.3
Li, Q.4
Chang, D.Z.5
Wei, D.6
-
32
-
-
79551692141
-
Combined blockade of Src kinase and epidermal growth factor receptor with gemcitabine overcomes STAT3-mediated resistance of inhibition of pancreatic tumor growth
-
Nagaraj NS, Washington MK, Merchant NB. Combined blockade of Src kinase and epidermal growth factor receptor with gemcitabine overcomes STAT3-mediated resistance of inhibition of pancreatic tumor growth. Clin Cancer Res 2011;17:483-93.
-
(2011)
Clin Cancer Res
, vol.17
, pp. 483-493
-
-
Nagaraj, N.S.1
Washington, M.K.2
Merchant, N.B.3
-
33
-
-
0029045033
-
Stages of embryonic development of the zebra fish
-
Kimmel CB, Ballard WW, Kimmel SR, Ullmann B, Schilling TF. Stages of embryonic development of the zebra fish. Dev Dyn 1995;203:253-310.
-
(1995)
Dev Dyn
, vol.203
, pp. 253-310
-
-
Kimmel, C.B.1
Ballard, W.W.2
Kimmel, S.R.3
Ullmann, B.4
Schilling, T.F.5
-
34
-
-
79960222273
-
A novel xenograft model in zebrafish for high-resolution investigating dynamics of neovascularization in tumors
-
Zhao C, Wang X, Zhao Y, Li Z, Lin S, Wei Y, et al. A novel xenograft model in zebrafish for high-resolution investigating dynamics of neovascularization in tumors. PLoS ONE 2011;6:e21768.
-
(2011)
PLoS ONE
, vol.6
, pp. e21768
-
-
Zhao, C.1
Wang, X.2
Zhao, Y.3
Li, Z.4
Lin, S.5
Wei, Y.6
-
35
-
-
84875993686
-
Erlotinib prolongs survival in pancreatic cancer by blocking gemcitabine-induced MAPK signals
-
Miyabayashi K, Ijichi H, Mohri D, Tada M, Yamamoto K, Asaoka Y, et al. Erlotinib prolongs survival in pancreatic cancer by blocking gemcitabine-induced MAPK signals. Cancer Res 2013;73:2221-34.
-
(2013)
Cancer Res
, vol.73
, pp. 2221-2234
-
-
Miyabayashi, K.1
Ijichi, H.2
Mohri, D.3
Tada, M.4
Yamamoto, K.5
Asaoka, Y.6
-
36
-
-
77955505020
-
Targeted inhibition of SRC kinase signaling attenuates pancreatic tumorigenesis
-
Nagaraj NS, Smith JJ, Revetta F, Washington MK, Merchant NB. Targeted inhibition of SRC kinase signaling attenuates pancreatic tumorigenesis. Mol Cancer Ther 2010;9:2322-32.
-
(2010)
Mol Cancer Ther
, vol.9
, pp. 2322-2332
-
-
Nagaraj, N.S.1
Smith, J.J.2
Revetta, F.3
Washington, M.K.4
Merchant, N.B.5
-
37
-
-
0032771840
-
The Trk tyrosine kinase inhibitor CEP-701 (KT-5555) exhibits significant antitumor efficacy in preclinical xenograft models of human pancreatic ductal adenocarcinoma
-
Miknyoczki SJ, Chang H, Klein-Szanto A, Dionne CA, Ruggeri BA. The Trk tyrosine kinase inhibitor CEP-701 (KT-5555) exhibits significant antitumor efficacy in preclinical xenograft models of human pancreatic ductal adenocarcinoma. Clin Cancer Res 1999;5:2205-12.
-
(1999)
Clin Cancer Res
, vol.5
, pp. 2205-2212
-
-
Miknyoczki, S.J.1
Chang, H.2
Klein-Szanto, A.3
Dionne, C.A.4
Ruggeri, B.A.5
-
38
-
-
0142214848
-
Heme oxygenase-1 accelerates tumor angiogenesis of human pancreatic cancer
-
Sunamura M, Duda DG, Ghattas MH, Lozonschi L, Motoi F, Yamauchi J, et al. Heme oxygenase-1 accelerates tumor angiogenesis of human pancreatic cancer. Angiogenesis 2003;6:15-24.
-
(2003)
Angiogenesis
, vol.6
, pp. 15-24
-
-
Sunamura, M.1
Duda, D.G.2
Ghattas, M.H.3
Lozonschi, L.4
Motoi, F.5
Yamauchi, J.6
-
39
-
-
33646577163
-
Genetics and biology of pancreatic ductal adenocarcinoma
-
Hezel AF, Kimmelman AC, Stanger BZ, Bardeesy N, Depinho RA. Genetics and biology of pancreatic ductal adenocarcinoma. Genes Dev 2006;20:1218-49.
-
(2006)
Genes Dev
, vol.20
, pp. 1218-1249
-
-
Hezel, A.F.1
Kimmelman, A.C.2
Stanger, B.Z.3
Bardeesy, N.4
Depinho, R.A.5
-
40
-
-
67650924582
-
Pancreatic cancer: Molecular pathogenesis and new therapeutic targets
-
Wong HH, Lemoine NR. Pancreatic cancer: molecular pathogenesis and new therapeutic targets. Nat Rev Gastroenterol Hepatol 2009;6:412-22.
-
(2009)
Nat Rev Gastroenterol Hepatol
, vol.6
, pp. 412-422
-
-
Wong, H.H.1
Lemoine, N.R.2
-
41
-
-
57349147100
-
Inhibition of Src tyrosine kinase reverts chemoresistance toward 5-fluorouracil in human pancreatic carcinoma cells: An involvement of epidermal growth factor receptor signaling
-
Ischenko I, Camaj P, Seeliger H, Kleespies A, Guba M, De Toni EN, et al. Inhibition of Src tyrosine kinase reverts chemoresistance toward 5-fluorouracil in human pancreatic carcinoma cells: an involvement of epidermal growth factor receptor signaling. Oncogene 2008;27:7212-22.
-
(2008)
Oncogene
, vol.27
, pp. 7212-7222
-
-
Ischenko, I.1
Camaj, P.2
Seeliger, H.3
Kleespies, A.4
Guba, M.5
De Toni, E.N.6
-
42
-
-
20944441928
-
Validating Stat3 in cancer therapy
-
Darnell JE. Validating Stat3 in cancer therapy. Nat Med 2005;11:595-6.
-
(2005)
Nat Med
, vol.11
, pp. 595-596
-
-
Darnell, J.E.1
-
43
-
-
72549108620
-
Reciprocal regulation of c-Src and STAT3 in non-small cell lung cancer
-
Byers LA, Sen B, Saigal B, Diao L, Wang J, Nanjundan M, et al. Reciprocal regulation of c-Src and STAT3 in non-small cell lung cancer. Clin Cancer Res 2009;15:6852-61.
-
(2009)
Clin Cancer Res
, vol.15
, pp. 6852-6861
-
-
Byers, L.A.1
Sen, B.2
Saigal, B.3
Diao, L.4
Wang, J.5
Nanjundan, M.6
-
44
-
-
0035799531
-
Constitutive activation of Stat3 by the Src and JAK tyrosine kinases participates in growth regulation of human breast carcinoma cells
-
Garcia R, Bowman TL, Niu G, Yu H, Minton S, Muro-Cacho CA, et al. Constitutive activation of Stat3 by the Src and JAK tyrosine kinases participates in growth regulation of human breast carcinoma cells. Oncogene 2001;20:2499-513.
-
(2001)
Oncogene
, vol.20
, pp. 2499-2513
-
-
Garcia, R.1
Bowman, T.L.2
Niu, G.3
Yu, H.4
Minton, S.5
Muro-Cacho, C.A.6
-
45
-
-
79953756112
-
Stat3/Socs3 activation by IL-6 transsignaling promotes progression of pancreatic intraepithelial neoplasia and development of pancreatic cancer
-
Lesina M, Kurkowski MU, Ludes K, Rose-John S, Treiber M, Kloppel G, et al. Stat3/Socs3 activation by IL-6 transsignaling promotes progression of pancreatic intraepithelial neoplasia and development of pancreatic cancer. Cancer Cell 2011;19:456-69.
-
(2011)
Cancer Cell
, vol.19
, pp. 456-469
-
-
Lesina, M.1
Kurkowski, M.U.2
Ludes, K.3
Rose-John, S.4
Treiber, M.5
Kloppel, G.6
-
46
-
-
79953761842
-
Stat3 and MMP7 contribute to pancreatic ductal adenocarcinoma initiation and progression
-
Fukuda A, Wang SC, Morris JPt, Folias AE, Liou A, Kim GE, et al. Stat3 and MMP7 contribute to pancreatic ductal adenocarcinoma initiation and progression. Cancer Cell 2011;19:441-55.
-
(2011)
Cancer Cell
, vol.19
, pp. 441-455
-
-
Fukuda, A.1
Wang, S.C.2
Morris, J.3
Folias, A.E.4
Liou, A.5
Kim, G.E.6
|